Antibiotic resistance mechanisms of clinically important bacteria
Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resista...
Gespeichert in:
Veröffentlicht in: | Medicina (Kaunas, Lithuania) Lithuania), 2011-01, Vol.47 (3), p.137-146 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 146 |
---|---|
container_issue | 3 |
container_start_page | 137 |
container_title | Medicina (Kaunas, Lithuania) |
container_volume | 47 |
creator | Giedraitienė, Agnė Vitkauskienė, Astra Naginienė, Rima Pavilonis, Alvydas |
description | Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resistance, (ii) gene transfer from one microorganism to other by plasmids (conjugation or transformation), transposons (conjugation), integrons and bacteriophages (transduction). After a bacterium gains resistance genes to protect itself from various antimicrobial agents, bacteria can use several biochemical types of resistance mechanisms: antibiotic inactivation (interference with cell wall synthesis, e.g., β-lactams and glycopeptide), target modification (inhibition of protein synthesis, e.g., macrolides and tetracyclines; interference with nucleic acid synthesis, e.g., fluoroquinolones and rifampin), altered permeability (changes in outer membrane, e.g., aminoglycosides; new membrane transporters, e.g., chloramphenicol), and "bypass" metabolic pathway (inhibition of metabolic pathway, e.g., trimethoprim-sulfamethoxazole). |
doi_str_mv | 10.3390/medicina47030019 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_893265663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>893265663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-234f95c900acb28c724be39f485791c7c87db6b9e57dd73a0ed44234ddd4aa2c3</originalsourceid><addsrcrecordid>eNpdkDtPwzAUhS0EoqWwM6FsTIHrR-J4jCoKSJVYYI7sa0cY5VFsZ-i_J6gFIaZ7pPt9ZziEXFO441zBfe-sRz9oIYEDUHVClrQUVa6oEKd_8oJcxPgBwFkh2TlZMFoxBrxYkroekjd-TB6z4KKPSQ_ost7hux587GM2thl2fvCou26f-X43hplJmdGYXPD6kpy1uovu6nhX5G3z8Lp-yrcvj8_repsjk5ByxkWrClQAGg2rUDJhHFetqAqpKEqspDWlUa6Q1kquwVkhZslaK7RmyFfk9tC7C-Pn5GJqeh_RdZ0e3DjFplKclUVZ8pmEA4lhjDG4ttkF3-uwbyg037s1_3eblZtj-WTm56_wMxT_AtKFa3Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>893265663</pqid></control><display><type>article</type><title>Antibiotic resistance mechanisms of clinically important bacteria</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Giedraitienė, Agnė ; Vitkauskienė, Astra ; Naginienė, Rima ; Pavilonis, Alvydas</creator><creatorcontrib>Giedraitienė, Agnė ; Vitkauskienė, Astra ; Naginienė, Rima ; Pavilonis, Alvydas</creatorcontrib><description>Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resistance, (ii) gene transfer from one microorganism to other by plasmids (conjugation or transformation), transposons (conjugation), integrons and bacteriophages (transduction). After a bacterium gains resistance genes to protect itself from various antimicrobial agents, bacteria can use several biochemical types of resistance mechanisms: antibiotic inactivation (interference with cell wall synthesis, e.g., β-lactams and glycopeptide), target modification (inhibition of protein synthesis, e.g., macrolides and tetracyclines; interference with nucleic acid synthesis, e.g., fluoroquinolones and rifampin), altered permeability (changes in outer membrane, e.g., aminoglycosides; new membrane transporters, e.g., chloramphenicol), and "bypass" metabolic pathway (inhibition of metabolic pathway, e.g., trimethoprim-sulfamethoxazole).</description><identifier>ISSN: 1648-9144</identifier><identifier>EISSN: 1648-9144</identifier><identifier>DOI: 10.3390/medicina47030019</identifier><identifier>PMID: 21822035</identifier><language>eng</language><publisher>Switzerland</publisher><subject>Anti-Bacterial Agents - metabolism ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Bacteria - classification ; Bacteria - drug effects ; Bacterial Infections - drug therapy ; Bacterial Infections - microbiology ; Cell Membrane Permeability ; Drug Resistance, Bacterial</subject><ispartof>Medicina (Kaunas, Lithuania), 2011-01, Vol.47 (3), p.137-146</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c270t-234f95c900acb28c724be39f485791c7c87db6b9e57dd73a0ed44234ddd4aa2c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21822035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Giedraitienė, Agnė</creatorcontrib><creatorcontrib>Vitkauskienė, Astra</creatorcontrib><creatorcontrib>Naginienė, Rima</creatorcontrib><creatorcontrib>Pavilonis, Alvydas</creatorcontrib><title>Antibiotic resistance mechanisms of clinically important bacteria</title><title>Medicina (Kaunas, Lithuania)</title><addtitle>Medicina (Kaunas)</addtitle><description>Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resistance, (ii) gene transfer from one microorganism to other by plasmids (conjugation or transformation), transposons (conjugation), integrons and bacteriophages (transduction). After a bacterium gains resistance genes to protect itself from various antimicrobial agents, bacteria can use several biochemical types of resistance mechanisms: antibiotic inactivation (interference with cell wall synthesis, e.g., β-lactams and glycopeptide), target modification (inhibition of protein synthesis, e.g., macrolides and tetracyclines; interference with nucleic acid synthesis, e.g., fluoroquinolones and rifampin), altered permeability (changes in outer membrane, e.g., aminoglycosides; new membrane transporters, e.g., chloramphenicol), and "bypass" metabolic pathway (inhibition of metabolic pathway, e.g., trimethoprim-sulfamethoxazole).</description><subject>Anti-Bacterial Agents - metabolism</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacteria - classification</subject><subject>Bacteria - drug effects</subject><subject>Bacterial Infections - drug therapy</subject><subject>Bacterial Infections - microbiology</subject><subject>Cell Membrane Permeability</subject><subject>Drug Resistance, Bacterial</subject><issn>1648-9144</issn><issn>1648-9144</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkDtPwzAUhS0EoqWwM6FsTIHrR-J4jCoKSJVYYI7sa0cY5VFsZ-i_J6gFIaZ7pPt9ZziEXFO441zBfe-sRz9oIYEDUHVClrQUVa6oEKd_8oJcxPgBwFkh2TlZMFoxBrxYkroekjd-TB6z4KKPSQ_ost7hux587GM2thl2fvCou26f-X43hplJmdGYXPD6kpy1uovu6nhX5G3z8Lp-yrcvj8_repsjk5ByxkWrClQAGg2rUDJhHFetqAqpKEqspDWlUa6Q1kquwVkhZslaK7RmyFfk9tC7C-Pn5GJqeh_RdZ0e3DjFplKclUVZ8pmEA4lhjDG4ttkF3-uwbyg037s1_3eblZtj-WTm56_wMxT_AtKFa3Y</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Giedraitienė, Agnė</creator><creator>Vitkauskienė, Astra</creator><creator>Naginienė, Rima</creator><creator>Pavilonis, Alvydas</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>Antibiotic resistance mechanisms of clinically important bacteria</title><author>Giedraitienė, Agnė ; Vitkauskienė, Astra ; Naginienė, Rima ; Pavilonis, Alvydas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-234f95c900acb28c724be39f485791c7c87db6b9e57dd73a0ed44234ddd4aa2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anti-Bacterial Agents - metabolism</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacteria - classification</topic><topic>Bacteria - drug effects</topic><topic>Bacterial Infections - drug therapy</topic><topic>Bacterial Infections - microbiology</topic><topic>Cell Membrane Permeability</topic><topic>Drug Resistance, Bacterial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Giedraitienė, Agnė</creatorcontrib><creatorcontrib>Vitkauskienė, Astra</creatorcontrib><creatorcontrib>Naginienė, Rima</creatorcontrib><creatorcontrib>Pavilonis, Alvydas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medicina (Kaunas, Lithuania)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Giedraitienė, Agnė</au><au>Vitkauskienė, Astra</au><au>Naginienė, Rima</au><au>Pavilonis, Alvydas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic resistance mechanisms of clinically important bacteria</atitle><jtitle>Medicina (Kaunas, Lithuania)</jtitle><addtitle>Medicina (Kaunas)</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>47</volume><issue>3</issue><spage>137</spage><epage>146</epage><pages>137-146</pages><issn>1648-9144</issn><eissn>1648-9144</eissn><abstract>Bacterial resistance to antimicrobial drugs is an increasing health and economic problem. Bacteria may be innate resistant or acquire resistance to one or few classes of antimicrobial agents. Acquired resistance arises from: (i) mutations in cell genes (chromosomal mutation) leading to cross-resistance, (ii) gene transfer from one microorganism to other by plasmids (conjugation or transformation), transposons (conjugation), integrons and bacteriophages (transduction). After a bacterium gains resistance genes to protect itself from various antimicrobial agents, bacteria can use several biochemical types of resistance mechanisms: antibiotic inactivation (interference with cell wall synthesis, e.g., β-lactams and glycopeptide), target modification (inhibition of protein synthesis, e.g., macrolides and tetracyclines; interference with nucleic acid synthesis, e.g., fluoroquinolones and rifampin), altered permeability (changes in outer membrane, e.g., aminoglycosides; new membrane transporters, e.g., chloramphenicol), and "bypass" metabolic pathway (inhibition of metabolic pathway, e.g., trimethoprim-sulfamethoxazole).</abstract><cop>Switzerland</cop><pmid>21822035</pmid><doi>10.3390/medicina47030019</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1648-9144 |
ispartof | Medicina (Kaunas, Lithuania), 2011-01, Vol.47 (3), p.137-146 |
issn | 1648-9144 1648-9144 |
language | eng |
recordid | cdi_proquest_miscellaneous_893265663 |
source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Anti-Bacterial Agents - metabolism Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Bacteria - classification Bacteria - drug effects Bacterial Infections - drug therapy Bacterial Infections - microbiology Cell Membrane Permeability Drug Resistance, Bacterial |
title | Antibiotic resistance mechanisms of clinically important bacteria |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T07%3A25%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20resistance%20mechanisms%20of%20clinically%20important%20bacteria&rft.jtitle=Medicina%20(Kaunas,%20Lithuania)&rft.au=Giedraitien%C4%97,%20Agn%C4%97&rft.date=2011-01-01&rft.volume=47&rft.issue=3&rft.spage=137&rft.epage=146&rft.pages=137-146&rft.issn=1648-9144&rft.eissn=1648-9144&rft_id=info:doi/10.3390/medicina47030019&rft_dat=%3Cproquest_cross%3E893265663%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=893265663&rft_id=info:pmid/21822035&rfr_iscdi=true |